Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Eledon Pharamceuticals (NASDAQ: ELDN).The analyst commented, "ELDN reported positive data ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments